IMPACT OF CYP2C9 GENOTYPE ON PHARMACOKINETICS: ARE ALL CYCLOOXYGENASE INHIBITORS THE SAME?

@article{Rodrigues2005IMPACTOC,
  title={IMPACT OF CYP2C9 GENOTYPE ON PHARMACOKINETICS: ARE ALL CYCLOOXYGENASE INHIBITORS THE SAME?},
  author={A. D. Rodrigues},
  journal={Drug Metabolism and Disposition},
  year={2005},
  volume={33},
  pages={1567 - 1575}
}
  • A. D. Rodrigues
  • Published 2005
  • Medicine
  • Drug Metabolism and Disposition
  • The market withdrawals of rofecoxib (Vioxx) and valdecoxib (Bextra) have focused considerable attention on the side effect profiles of cyclooxygenase (COX) inhibitors. As a result, attempts will be made to identify risk factors in the hope that physicians might be able to ensure patient safety. At first glance, CYP2C9 genotype might be considered a risk factor because many COX inhibitors are CYP2C9 substrates in vitro. This observation has led some to hypothesize that a reduction in clearance… CONTINUE READING
    99 Citations
    Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.
    • 110
    Pharmacogenomics of CYP2C9: Functional and Clinical Considerations†
    • 45
    • PDF
    The Role of Pharmacogenetics in the Metabolism of Antiepileptic Drugs
    • U. Klotz
    • Biology, Medicine
    • Clinical pharmacokinetics
    • 2007
    • 138
    Clinical pharmacology of celecoxib, a COX-2 selective inhibitor
    • 24
    • Highly Influenced
    Molecular functionality of CYP2C9 polymorphisms and their influence on drug therapy
    • 14
    Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam.
    • 12

    References

    SHOWING 1-10 OF 145 REFERENCES
    CYP2C9 genotype as a predictor of drug disposition in humans.
    • C. Lee
    • Medicine
    • Methods and findings in experimental and clinical pharmacology
    • 2004
    • 24
    Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.
    • 110
    • Highly Influential
    Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences.
    • 90
    Cytochrome P450 2C9 genotype: Impact on celecoxib safety and pharmacokinetics in a pediatric patient
    • 23
    Clinical Consequences of Cytochrome P450 2C9 Polymorphisms
    • 448
    Pharmacokinetics of Rofecoxib
    • 24
    Cytochrome P450 2C8: Substrates, Inhibitors, Pharmacogenetics, and Clinical Relevance
    • 212
    • Highly Influential
    Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.
    • 795
    • PDF
    Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics.
    • 221
    • PDF
    Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype.
    • 44
    • Highly Influential